Neglected diseases, primarily found in tropical regions of the world, present a significant
challenge for impoverished populations. Currently, there are 20 diseases considered …

Covering: up to April 2020 Proteases are involved in the regulation of many physiological
processes. Their overexpression and dysregulated activity are linked to diseases such as …

The protozoa, Trypanosoma cruzi (etiological agent of Chagas diseases–also named
American trypanosomiasis) and T. brucei (causative agent of human African …

Schistosomiasis, caused by a parasitic blood fluke of the genus Schistosoma, is a global
health problem for which new chemotherapeutic options are needed. We explored the …

Leishmaniasis is an infectious disease caused by protozoan parasites from the Leishmania
genus, representing a significant global public health issue that affects thousands of …

The current 2019–2021 marine pharmacology literature review provides a continuation of
previous reviews covering the period 1998 to 2018. Preclinical marine pharmacology …

Current small-molecule-based SARS-CoV-2 treatments have limited global accessibility and
pose the risk of inducing viral resistance. Therefore, a marine algae and cyanobacteria …

Iheyamide A (1) is an antitrypanosomal linear peptide isolated from a Dapis sp. marine
cyanobacterium by our group in 2020, and based on structure–activity relationships of its …

The cysteine protease cruzipain is considered to be a validated target for therapeutic
intervention in the treatment of Chagas disease. A series of 26 new compounds were …

Aim: Discovery of novel SARS-CoV-2 main protease (Mpro) inhibitors using a structure-
based drug discovery strategy. Materials & methods: Virtual screening employing covalent …